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Modeling of the Weight Status and Risk of Nonalcoholic
Fatty Liver Disease in Elderly Individuals: The Potential
Impact of the Disulfide Bond-Forming Oxidoreductase
A-Like Protein (DsbA-L) Polymorphism on the Weight
Status
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Katsuya Nagaoka2, Tadashi Imafuku3, Yu Ishima4, Hiroshi Watanabe3, Toru Maruyama3, Koji Otake5, Yasuhiro Ogata2
and Junji Saruwatari1,6*
Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity. Disulfide bond-forming oxidoreductase A-like
protein (DsbA-L) is known to be a key molecule in protection against obesity and obesity-induced inflammation. In the present
study, we used a modeling and simulation approach in an attempt to develop body mass index (BMI) and BMI-based NAFLD
prediction models incorporating the DsbA-L polymorphism to predict the BMI and NAFLD in 341 elderly subjects. A nonlinear
mixed-effect model best represented the sigmoidal relationship between the BMI and the logit function of the probability of
NAFLD prevalence. The final models for BMI and NAFLD showed that DsbA-L rs1917760 polymorphism, age, and gender were
associated with the BMI, whereas gender, patatin-like phospholipase 3 rs738409 polymorphism, HbA1c, and high-density and
low-density lipoprotein cholesterol levels were associated with the risk of NAFLD. This information may aid in the genetic-
based prevention of obesity and NAFLD in the general elderly population.
CPT Pharmacometrics Syst. Pharmacol. (2018) 7, 384–393; doi:10.1002/psp4.12292; published online 30 March 2018.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Although obesity is closely associated with the devel-
opment and progression of NAFLD, at present, no models
incorporating detailed population background information
can adequately predict the association between the
weight status and NAFLD. Several experimental models
showed that DsbA-L is known as a key molecule in pro-
tecting against obesity and obesity-induced inflamma-
tion and insulin resistance; however, it is totally unclear
whether DsbA-L polymorphism is associated with the
weight status or NAFLD in humans.
WHAT QUESTION DID THIS STUDY ADDRESS?
 This study addresses the how the weight status is asso-
ciated with the risk of developing NAFLD, and how func-
tional polymorphism of DsbA-L (rs1917760, -1308G>T) is
potentially associated with the weight status and the risk of
NAFLD in the elderly general population using a NONMEM
approach and structural equation modeling.
WHAT DOES THIS STUDY ADD TO OUR
KNOWLEDGE?
 This study adds information regarding: (1) a popula-
tion prediction model for predicting the risk of NAFLD,
which can be shown as a sigmoidal maximum response
using the BMI as an exposure variable; and (2) the clin-
ical implications of the DsbA-L rs1917760 polymor-
phism, which is associated with the weight status, and
which is possibly indirectly associated with the risk of
NAFLD in the general elderly population.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS?
 The results of this study suggest that the DsbA-L
may be an effective target for preventing or treating
obesity, especially in DsbA-L T/T genotype carriers. In
addition, the modeling and simulation procedure of this
study may contribute to the further development of
genetic-based prediction models for other metabolic
diseases.
Nonalcoholic fatty liver disease (NAFLD) is the hepatic
manifestation of metabolic syndrome, which is an indepen-
dent risk factor for type 2 diabetes, cardiovascular disease,
and its related future events.1–3 NAFLD is particularly com-
mon in elderly people, and elderly patients with NAFLD
have a high risk of strongly aging-related metabolic
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complications (i.e., type 2 diabetes and cardiovascular dis-
ease).1,4 Experimental and epidemiological evidence have
shown that obesity is closely associated with the develop-
ment and progression of NAFLD.1–3 However, NAFLD can
also be observed in subjects with a normal-weight (body
mass index (BMI) <25 kg/m2), especially in Asian popula-
tions.1,5 We recently reported that patatin-like phospholi-
pase domain-containing 3 (PNPLA3) rs738409, a well-
known polymorphism that predisposes carriers for a fatty
liver,6 was associated with a risk of developing NAFLD,
even in individuals with a normal weight status.7 Thus, the
population background (e.g., genetic polymorphisms, life-
style, age, gender, and underlying diseases) should be
carefully considered when determining the association
between the weight status and the risk of NAFLD; how-
ever, at present, no population models incorporating
detailed population background information can predict
this association with sufficient accuracy.
Adiponectin, an adipose tissue-specific hormone, has
been reported to be associated with the protection against
adipose tissue inflammation, insulin resistance, and mito-
chondrial dysfunction and to have an important role in
the prevention of obesity and its related diseases.8–10
Plasma adiponectin exists as a low-molecular-weight trimer,
medium-molecular-weight hexamer, and high-molecular-
weight (HMW) oligomer.10 HMW oligomers of adiponectin
are the major relevant forms for improving insulin sensitivity,
anti-inflammatory and antidiabetic activities, and low levels
of HMW oligomers represent an independent risk factor for
several metabolic diseases.10 Thus, adiponectin multimeri-
zation, which requires disulfide bond formation between
two different trimers,11,12 may play a crucial role in the pre-
vention of metabolic disease.
Disulfide bond-forming oxidoreductase A-like protein
(DsbA-L), a renamed protein from glutathione S-transferase
kappa 1, is highly expressed in the endoplasmic reticulum
and mitochondria and plays an important role in disulfide
bond formation and antioxidant action.13–15 DsbA-L is con-
sidered to be a key regulator of adiponectin multimerization
in 3T3-L1 cells that are most commonly used as an adipo-
cyte differentiation model.14 In addition, it has been reported
that the mRNA level of DsbA-L in adipose tissue correlated
negatively with obesity in both mice and humans.13,14 Chen
et al.16 showed that the liver-specific knock-out of DsbA-L in
mice exacerbated high-fat diet-induced hepatosteatosis, and
the overexpression of DsbA-L protected mice against hepa-
tosteatosis and insulin resistance. Furthermore, the sup-
pression of DsbA-L is associated with the impairment of the
respiratory capacity in mitochondria and the elevation of cel-
lular oxidative stress.16 Recently, Bai et al.17 revealed DsbA-
L as a key molecule in protecting obesity-induced inflamma-
tion and insulin resistance by suppressing the cGMP-AMP
(cGAMP) synthase (cGAS)-cGAMP-stimulator of interferon
genes (STING) pathway, which mediates DNA sensing and
signaling and is involved in the lipotoxic activation of Tank-
binding protein kinase 1 and subsequent p62 phosphoryla-
tion in hepatocytes.18,19 Thus, in humans, the DsbA-L poly-
morphisms may play a key role in the development and/or
progression of obesity and obesity-induced liver diseases
(e.g., NAFLD).
A common polymorphism in the DsbA-L gene at -1308
bp (rs1917760) can influence the DsbA-L function and/or
expression.20 Among Asians, the rs1917760 polymorphism
has previously been described with an allele frequency of
20%20; however, the polymorphism was not detected
among European and African populations. Our recent
cross-sectional study indicated that the DsbA-L rs1917760
polymorphism is associated with decreased levels of DsbA-
L mRNA in peripheral blood mononuclear cells and an
increased prevalence of being overweight among male Jap-
anese patients with schizophrenia.21 Given these findings,
the DsbA-L polymorphism may play a critical role in the
development of obesity and NAFLD; however, the clinical
roles of the DsbA-L polymorphism in weight gain and the
development of NAFLD, including its relationship to adipo-
nectin, oxidative stress, and environmental factors, remain
unknown.
Pharmacometrics is a relatively recently established sci-
ence that provides quantitative models regarding the phar-
macology through the mathematical modeling of clinical
efficacy based on multivariable analyses.22–25 A nonlinear
mixed-effect model (NONMEM) is a pharmacometric pro-
cedure that is widely applied in pharmacokinetic (PK) and
PK/pharmacodynamic (PD) analyses based on longitudi-
nal data, which enables the examination of various base
models and the effects of various cofactors, the utilization
of all observation points, and the evaluation of validity
based on simulation.22–25 On the other hand, disease pro-
gression models are often integrated with PK/PD models
using a NONMEM approach to quantify the influence of
various factors on disease progression because of the
ability to quantify several levels of variability, to address
instability data, and to identify individual specific cofac-
tors.22,23 Thus, a NONMEM approach can be an effective
tool for developing a disease prediction model using clini-
cal information and to help clarify the precise effects of
various factors on disease development and progression.
Structural equation modeling is a multivariable statistical
method that involves the estimation of parameters for a
system of simultaneous equations, including regression
analyses, pathway analyses, factor analyses, simultaneous
econometric equations, and latent growth curve models.26
Structural equation modeling, which has been widely used
in medical sciences, including clinical studies, enables the
identification of direct or indirect relationships among pre-
dictors, mediators, and clinical outcomes.26 It is a general
and powerful approach that accounts for measurement
error and causal pathways by estimating the parameters for
a system of simultaneous equations.27 Thus, structural
equation modeling is another useful tool for modeling the
associations between massive patient information and com-
plex systems of multiple phenotypes.27,28
In the present study, we applied NONMEM using genetic
and longitudinal clinical data to characterize the weight sta-
tus and the risk of developing NAFLD in elderly Japanese
subjects who participated in a health screening program. The
primary objective of this study was to investigate the potential
impact of the DsbA-L rs1917760 polymorphism on the weight
status and the risk for NAFLD in the elderly general popula-
tion using the prediction models of BMI and risk for NAFLD




constructed by a NONMEM program. In addition, we ana-
lyzed the association among the DsbA-L genotype, BMI,
NAFLD, and their related covariates (e.g., adiponectin multi-
merization) using structural equation modeling.
MATERIALS AND METHODS
Subjects and study protocol
All subjects were Japanese participants in the elderly health
screening program held by the Japanese Red Cross Kuma-
moto Health Care Center. A retrospective longitudinal anal-
ysis with a follow-up period of 5.5 6 1.1 years was
conducted among 341 subjects who did not have a habitual
alcohol intake (consumption of >30 g/day of alcohol in men
or >20 g/day in women) and/or were not hepatitis B or C
virus-positive, in accordance with the previously reported
practical guidelines for NAFLD.29 The study complies with
the Declaration of Helsinki, and was approved by the ethics
committees of the Faculty of Life Sciences at Kumamoto
University and the Japanese Red Cross Kumamoto Health
Care Center. All the subjects provided their written informed
consent prior to enrollment in the study. All analyses were
performed in accordance with Ethical Guidelines for Epide-
miological Research in Japan.
Measurements
Overweight and normal-weight statuses were defined as
BMI 25 kg/m2 and BMI <25 kg/m2, respectively. Hepatic
ultrasonography scanning was used to diagnose fatty liver
disease (FLD). The FLD was diagnosed based on the fol-
lowing four criteria: (1) a diffuse hyperechoic echotexture
(bright liver); (2) an increased echo texture in comparison
to the kidneys; (3) vascular blurring; and (4) deep
attenuation.29
Genotyping
Genomic DNA was extracted from whole blood using a
DNA purification kit (FlexiGene DNA kit; QIAGEN, Hilden,
Germany). DsbA-L rs1917760 (-1308G>T) and PNPLA3
rs738409 (c.444C>G, encoding I148M) genotypes were
determined using a real-time TaqMan allelic discrimination
assay (Applied Biosystems, Waltham, MA) in accordance
with the manufacturer’s protocol (DsbA-L, assay no.
C_11980950_10; PNPLA3, assay no. C_7241_10). To
ensure the genotyping quality, we included DNA samples
as internal controls, hidden samples of a known geno-
type, and negative controls (water).
Measurement of adiponectin
The levels of total and HMW adiponectin were measured
using fasting serum samples that were collected at the
end of the observation period. Concentrations of total and
HMW adiponectin in fasting serum samples were deter-
mined by enzyme-linked immunosorbent assay (ELISA)
kits with intra-assay coefficients of variation of 2.5–4.7%
and 2.6–3.7%, respectively, and with interassay coeffi-
cients of variation of 5.8–6.9% and 8.3–8.6%, respectively
(Human Total Adiponectin/Acrp30 and Human HMW Adi-
ponectin/Acrp30 Quantikine ELISA Kits; R&D Systems,
Minneapolis, MN). These ELISA assays were performed
in accordance with the manufacturer’s protocol.
Measurement of oxidized human serum albumin
The redox state of human serum albumin (HSA) was used
as a systemic oxidative stress marker, as it reflects the pro-
gression of oxidative stress-related chronic diseases.30,31
The redox state of HSA was analyzed by high-performance
liquid chromatography for the fasting serum samples that
were collected at the end point of the observation period,
as described in a previous study for assessing the level of
oxidative stress.32 Based on the high-performance liquid
chromatography profiles of HSA, the values of each of the
albumin fractions (for human mercapto-albumin, human
non-mercapto-albumin (HNA)1 and HNA2) were esti-
mated by dividing the area of each fraction by the total
area corresponding to HSA. A mixture of HNA1 and
HNA2 was defined as oxidized HSA.
Statistical analyses
The details of the statistical analyses are shown in the
Supplementary Materials and Methods.
RESULTS
Clinical characteristics of the subjects at baseline
The observed genotype frequency distributions of the
DsbA-L and PNPLA3 were consistent with the Hardy-
Weinberg equilibrium (P> 0.05). The demographic charac-
teristics at baseline of the subjects stratified by the DsbA-L
genotypes are shown in Table 1. The longitudinal differ-
ences in the BMI and the cumulative prevalence of NAFLD
between the DsbA-L genotypes are shown in Figure 1.
Although the BMI at baseline did not differ among patients
with the DsbA-L genotypes (Table 1), the BMI was higher
in carriers of the DsbA-L T/T genotype than in those with
the G/G or G/T genotypes during the observation period
that was analyzed using the generalized estimating equa-
tions approach (P 5 0.013; Figure 1). The prevalence
of NAFLD at baseline did not differ among the DsbA-L
genotypes (Table 1), and no significant association was
found between the cumulative prevalence of NAFLD
and the DsbA-L genotypes during the observation period
(P 5 0.128; Figure 1).
Development of a model describing the interindividual
variability in the BMI values
First, we developed a model describing the interindividual
variability in the BMI values. Because the mean value of
BMI was nearly unchanged during the observation period
(Figure 1), we developed a model for BMI using a linear
regression model. Supplementary Table S1 shows the
effects of the tested covariates on the objective function of
the parameters regarding modeling for the BMI. Age, gen-
der, and DsbA-L genotype were significantly associated
with the BMI. The final model for BMI was as follows:
BMI522:63 AGE=70:8ð Þ20:07130:968female11:50DsbALT=Tgenotype (1)
Female 5 1 for females, and 0 for males; DsbA-L T/T
genotype 5 1 for carriers of the T/T genotype, and 0 for
noncarriers (i.e., carriers of DsbA-L G/G or G/T genotype).
This BMI model indicated that age, female gender, and
DsbA-L T/T genotype were associated with BMI (Eq. 1).
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The results showed that the BMI in the DsbA-L T/T geno-
type was higher by 1.5 kg/m2 than that of the G/G or G/T
genotype carriers (Eq. 1).
Development of the prediction model for NAFLD
Next, we developed the base model of the risk for NAFLD
using a logistic regression model. Because the develop-
ment of NAFLD is closely related to the presence of obe-
sity, the logit (probability (Pr)) value of the model was a
sigmoidal maximum response of the prevalence for NAFLD
using BMI as the exposure variable. Supplementary
Table S2 shows the effects of the tested covariates on the
objective function of the parameters regarding the risk of
developing NAFLD. Female gender; levels of high-density
lipoprotein cholesterol (HDL-C), low-density lipoprotein cho-
lesterol (LDL-C), and HbA1c; and a PNPLA3 genotype
were significantly associated with the risk of developing
NAFLD. However, the DsbA-L genotype had no effect on the
risk of developing NAFLD. The final prediction model for the
risk of NAFLD was as follows:
LogitðPrÞ5251 LogitðPr Þmax 3 BMI217ð Þ
3:43
BMI50217ð Þ3:431 BMI217ð Þ3:43
(2)
Logit Prð Þmax 54:1711:02female20:0603 HDL269:4ð Þ
10:0093 LDL2120ð Þ (3)
BMI5051716:4230:760
PNPLA3 C=G genotype
30:591PNPLA3 C=G genotype3 HbA1c=5:88ð Þ23:34 (4)
where Logit(Pr)max is the maximum value of the logit
regarding the prevalence of NAFLD; BMI50 is the BMI cor-
responding to 50% of the Logit(Pr)max; female 5 1 if female,
and 0 if male; PNPLA3 C/G genotype or PNPLA3 G/G
genotype 5 1 for carriers of each genotype, and 0 for
carriers of other genotypes. This NAFLD model indicated
that the risk of developing NAFLD increased with increas-
ing BMI (Eq. 2 and Figure 2). Female gender, a low value
of HDL-C, and a high value of LDL-C were associated
with an increased Logit(Pr)max (Eq. 3 and Figure 2). The
PNPLA3 rs738409 polymorphism and a high value of
HbA1c were associated with a decreased BMI50 (Eq. 4
and Figure 2). The DsbA-L genotype was not found to be
a significant covariate for the Ligit (Pr) of the risk of devel-
oping NAFLD. The results of model evaluation and simula-
tion are shown in the Supplementary Results. In order
to assess the effect of the DsbA-L genotype on
overweight-induced NAFLD, we also developed models for
NAFLD stratified by the weight status (i.e., overweight or
normal-weight; Supplementary Tables S2 and S4). How-
ever, no association was found between the DsbA-L geno-
type and the risk of developing NAFLD in either normal
weight or overweight subjects (Supplementary Tables S2
and S4).
Table 1 Clinical characteristics of all subjects at baseline
DsbA-L genotype
G/G (n 5 192) G/T (n 5 129) T/T (n 5 20) P value
Female (%) 80 (41.7) 56 (43.4) 9 (45.0) 0.928
Age, years 68.0 6 5.9 67.3 6 5.8 67.3 6 6.0 0.513
BMI, kg/m2 22.5 6 2.9 22.6 6 2.7 23.9 6 3.0 0.112
Waist circumstance, cm 82.2 6 8.3 82.9 6 7.3 83.8 6 6.7 0.691
Fasting blood glucose, mg/dL 99.7 6 18.8 104.0 6 23.2 102.9 6 8.2 0.200
HbA1c, % 5.80 6 0.63 5.88 6 0.75 5.91 6 0.45 0.500
Systolic blood pressure, mmHg 123.4 6 18.3 121.9 6 17.3 122.6 6 13.0 0.762
Diastolic blood pressure, mmHg 72.1 6 10.3 71.4 6 11.3 72.7 6 11.2 0.775
eGFR, mL/min/1.73 m2 72.1 6 14.5 72.1 6 11.6 75.6 6 15.9 0.541
LDL-C, mg/dL 125.9 6 27.3 125.5 6 25.9 121.0 6 25.6 0.747
HDL-C, mg/dL 69.7 6 16.1 68.8 6 16.3 71.2 6 23.8 0.799
TG, mg/dL 100.9 6 49.7 100.5 6 44.1 105.6 6 52.2 0.907
AST, IU/L 24.4 6 7.3 23.1 6 5.9 23.8 6 5.3 0.221
ALT, IU/L 21.7 6 10.0 21.2 6 9.3 23.3 6 7.0 0.653
GGT, IU/L 30.2 6 25.6 27.6 6 22.8 27.1 6 13.4 0.586
Overweight (%) 35 (18.2) 22 (17.1) 7 (35.0) 0.154
Diabetes (%) 22 (11.5) 19 (14.7) 2 (10.0) 0.644
Hypertension (%) 78 (40.6) 53 (41.1) 9 (45.0) 0.931
Dyslipidemia (%) 96 (50.0) 61 (47.3) 7 (35.0) 0.430
NAFLD (%) 27 (14.1) 19 (14.7) 5 (25.0) 0.435
Ever smoker (%) 57 (29.7) 51 (39.5) 6 (30.0) 0.176
Alcohol intake (g/day) 4.6 6 6.7 4.7 6 7.0 3.7 6 7.2 0.835
The data are the means 6 SD or proportions for categorical variables.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DsbA-L, disulfide bond-forming oxidoreductase A-like protein; eGFR,
estimated glomerular filtration rate; GGT, gamma-glutamyl transferase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
NAFLD, non-alcoholic fatty liver disease; TG, triglyceride.




Associations of the adiponectin levels with the DsbA-L
genotype
The median values (range) of total and HMW adiponectin
and the ratio of HMW to total adiponectin (i.e., index of adi-
ponectin multimerization) were 123.0 (7.9–542.6) ng/mL,
74.9 (3.4–350.7) ng/mL, and 0.65 (0.09–0.99), respectively.
The ratio of HMW to total adiponectin was significantly
lower in carriers of DsbA-L T/T genotype than in those with
Figure 2 The relationships between the body mass index (BMI) and
the logit of nonalcoholic fatty liver disease (NAFLD) prevalence
based on the prediction model for NAFLD. The effects of covariates
on the relationships between the BMI and the logit of NAFLD preva-
lence are indicated by arrows. (a) The relationship between the BMI
and the logit of NAFLD prevalence is shown as a solid curve for
average subjects. (b) The relationships between the BMI and the
logit of NAFLD prevalence are shown as a solid curve for female
subjects or subjects with a low value of high-density lipoprotein cho-
lesterol and/or a high value of low-density lipoprotein cholesterol, and
are shown as a dotted curve for average subjects. (c) The relation-
ship between the BMI and the logit of NAFLD prevalence are shown
as a solid curve for subjects with patatin-like phospholipase domain-
containing 3 (PNPLA3) C/G or G/G genotypes and/or a high value of
HbA1c and are shown as a dotted curve for average subjects.
Figure 1 Longitudinal changes in the mean values of body mass
index (BMI) and the cumulative prevalence of nonalcoholic fatty
liver disease (NAFLD) stratified by the disulfide bond-forming oxi-
doreductase A-like protein (DsbA-L) genotype. The mean values
of BMI (a) and the cumulative prevalence of NAFLD (b) are shown
as dashed-dotted, dotted, and solid lines for the subjects with the
DsbA-L G/G, G/T, and T/T genotypes, respectively. (a) The bars
represent the mean 6 SE. (b) The graph provides the best fit linear
lines of the cumulative prevalence of NAFLD (%). The bars repre-
sent the 95% confidence intervals, and the trigonal, cross, and
dimetric plots represent the actual measurements in the DsbA-L G/
G, G/T, and T/T genotypes, respectively. The coefficient of determi-
nations (R2) of the best fit linear lines in the DsbA-L G/G, G/T, and
T/T genotypes were 0.886, 0.740, and 0.783, respectively.
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the G/G or G/T genotype (Figure 3), and this association
was also observed in the multiple regression analysis
(Supplementary Table S5). An interactive effect of DsbA-L
genotype and overweight status (end point) on the ratio of
HMW to total adiponectin was observed (P< 0.05). There-
fore, we also analyzed the associations of the DsbA-L
genotype with the values of total and HMW adiponectin and
their ratio among normal weight and overweight subjects in
end point (Figure 3). Among overweight subjects, the ratio
of HMW to total adiponectin was significantly lower in carriers
of DsbA-L T/T genotype than in those with the G/G or G/T
genotype (Figure 3), and this association was also observed
in the multiple regression analysis (Supplementary Table S5).
In contrast, the DsbA-L T/T genotype was not associated with
the ratio of HMW to total adiponectin value among normal-
weight subjects (Figure 3 and Supplementary Table S5).
Association of the oxidized HSA with the DsbA-L
genotype
The median value (range) of oxidized HSA was 1.99
(1.53–2.64) g/dL. The median value (range) of oxidized
HSA was higher in subjects who were overweight than in
those with normal weight (2.05 (1.66–2.54) g/dL vs. 1.97
(1.53–2.64) g/dL; P 5 0.005; Supplementary Figure S2).
In addition, the median value (range) of oxidized HSA
was also higher in subjects with NAFLD than in those with
Figure 3 The effect of the disulfide bond-forming oxidoreductase A-like protein (DsbA-L) genotype on the adiponectin levels. Plots of
the values of total adiponectin (a), high-molecular-weight (HMW) adiponectin (b), and the ratio of HMW to total adiponectin (c) stratified
by the DsbA-L genotype are shown for all, overweight, and normal weight subjects. The P values were calculated by Mann-Whitney U-
test. *The significance remained after Bonferroni’s test.




non-NAFLD (2.07 (1.71–2.54) g/dL vs. 1.98 (1.53–2.64) g/dL;
P5 0.003; Supplementary Figure S2). Although the differ-
ences were not significant, the median values (ranges) of oxi-
dized HSA tended to be higher in the DsbA-L G/T or T/T
genotypes carriers (2.01 (1.64–2.64) g/dL or 2.06 (1.67–2.26)
g/dL) than in the G/G genotype carriers (1.96 (1.53–2.57) g/
dL; P 5 0.106 and P 5 0.417, respectively; Figure 4).
Among the normal weight subjects, the median value of oxi-
dized HSA was higher in the DsbA-L G/T than in the G/G
genotype carriers (1.99 (1.64–2.64) g/dL vs. 1.93 (1.53–
2.57) g/dL; P 5 0.027) but the significance disappeared
after Bonferroni’s adjustment (Figure 4).
Structural equation modeling
Finally, we evaluated the relationships among the DsbA-L
genotypes, BMI, the prevalence of NAFLD, and their related
covariates. Figure 5 shows the structural equation model
using the clinical data at the end point of the observation
period. The P value for the model fit to a v2 (18.40, degree of
freedom 5 17) was 0.364, and the goodness of fit index,
adjusted goodness of fit index, and root mean square error of
approximation were 0.987, 0.972, and 0.016, respectively.
Taken together, these fitness statistics indicated a good fit for
the structural equation model. The DsbA-L T/T genotype
seems to influence a high BMI both directly and indirectly
through a decreased HMW-to-total adiponectin ratio,
whereas the DsbA-L T/T genotype was not directly associ-
ated with the risk of developing NAFLD (Figure 5). A high
BMI and lower adiponectin multimerization were directly and/
or indirectly associated with the risk of NAFLD (Figure 5).
DISCUSSION
In the present study, we used a NONMEM program to
develop population prediction models incorporating popula-
tion background characteristics (e.g., the DsbA-L T/T
genotype) to predict the BMI and the risk of NAFLD in the
general elderly population. In this study, the population pre-
diction model for predicting the risk of NAFLD could be
shown as a sigmoidal maximum response using the BMI as
an exposure variable, and the interindividual variability in
the BMI values was described using a linear regression
model. The models we developed described the data ade-
quately (Supplementary Results, Supplementary Figure S1,
and Supplementary Tables S3 and S4). We expect that
these findings and/or the procedure of this study will aid in
the further prevention/treatment of obesity and obesity-
related diseases, such as NAFLD, in the general elderly pop-
ulation based on the population background.
This is the first study to show that the DsbA-L T/T geno-
type is associated with an increased BMI partially by
decreasing adiponectin multimerization. Although the DsbA-
L polymorphism did not affect the risk for NAFLD directly in
the prediction model of NAFLD, the structural equation
model suggested that the DsbA-L T/T genotype might affect
the risk of developing NAFLD through a high BMI in relation
to lowering adiponectin multimerization. A previous study
reported that DsbA-L was able to protect mice from high-
fat-diet-induced obesity, and the expression of DsbA-L
was inversely correlated with the BMI in both mice and
humans.13 DsbA-L rs1917760 polymorphism was also
associated with increased insulin secretion and fat deposi-
tion in humans.33 Thus, early intervention to upregulate
DsbA-L or enhance adiponectin multimerization (e.g., die-
tary intervention34) in DsbA-L T/T genotype carriers may be
an effective approach for preventing obesity in the elderly
population.
Low circulating levels of HMW adiponectin are a strong
risk factor for the development of visceral obesity.10 DsbA-L
is a key regulator of the adiponectin multimerization in 3T3-
L1 cells14 and protects mice from diet-induced obesity and
insulin resistance.13 Liu et al.35 showed that DsbA-L
Figure 4 The effect of the disulfide bond-forming oxidoreductase A-like protein (DsbA-L) genotype on the oxidized human serum albu-
min (HAS) level. Plots of the values of total oxidized HSA stratified by the DsbA-L genotype are shown for all, overweight, and normal
weight subjects. The P values were calculated by Mann-Whitney U-test. *The significance disappeared after Bonferroni’s test.
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localized in the endoplasmic reticulum, and this localization
was critical for suppressing endoplasmic reticulum stress
and promoting HMW adiponectin biosynthesis and secre-
tion. The present study revealed that the DsbA-L T/T geno-
type was associated with a high BMI as well as a low
HMW-to-total adiponectin ratio in relation to overweight sta-
tus in the general Japanese population (Eq. 1, Figures 1,
3, and 5, and Supplementary Table S5); however, this
genotype did not have any significant impact on the cumu-
lative prevalence of NAFLD (Figure 1) or the BMI-based
prediction model for the risk of NAFLD (Eqs. 2, 3, and 4).
Meanwhile, we found that a high BMI and lower adiponectin
multimerization were directly and/or indirectly associated
with the risk of NAFLD in our structural equation model
(Figure 5). Taken together, we hypothesize that the DsbA-L
T/T genotype may be indirectly and partially associated
with the risk of NAFLD through a high BMI and low adipo-
nectin multimerization.
Chen et al.16 showed that hepatic DsbA-L protects mice
from high-fat diet-induced fatty liver and insulin resistance.
More recently, the cGAS-cGAMP-STING pathway has been
identified as a cytosolic DNA sensor of pathogen-derived
DNA, which mediates the innate immune response.18 Bai
et al.17 showed that obesity-induced mtDNA is released
into cytosol resulting in inflammatory responses through the
activation of the cGAS-cGAMP-STING pathway. Moreover,
they identified DsbA-L as an important regulator of the
mitochondrial integrity and function, which suppresses the
activation of the cGAS-cGAMP-STING pathway resulting in
obesity-induced inflammation and insulin resistance.17
Thus, it is considered that DsbA-L may play a key role in
the development and progression of NAFLD, especially in
obese populations. In the present study, the association
between DsbA-L polymorphism and the median ratio of
HMW to total adiponectin, which is related to protection
against adipose tissue inflammation and insulin resis-
tance,8–10 was more pronounced in overweight subjects
than in the overall study population (Figure 3). However,
we did not find any direct effects of DsbA-L polymorphism
on the risk of NAFLD, even in overweight subjects (Eqs. 2,
3, and 4, and Supplementary Tables S2 and S4). In this
study, we could not investigate the association between
DsbA-L polymorphism and the risk of NAFLD in the obese
population, because the prevalence of obesity (BMI
30 kg/m2) among the study subjects (1.2%) was small.
Further larger studies will be needed to elucidate the poten-
tial impact of this polymorphism on the obesity-induced devel-
opment and progression of NAFLD in humans.
DsbA-L is expressed in both the mitochondria and the
endoplasmic reticulum in adipocytes,35 and it plays a role in
not only adiponectin multimerization but also antioxidant
protection.35,36 DsbA-L exerts activities against a number of
substrates associated with oxidative stress (e.g., l-chloro-
2,4-dinitrobenzene, ethacrynic acid, cumene hydroperoxide,
and t-butyl hydroperoxide).36 Furthermore, the knockdown
of DsbA-L in Caenorhabditis elegans resulted in a signifi-
cant decrease in the respiration rate and a change in the
fatty acid metabolism in mitochondria.37 The redox state of
HSA has been proposed as a plasma marker of chronic
oxidative stress-related diseases,30 including the progres-
sion of chronic hepatitis and cirrhosis.31 The results of this
study showed that the oxidized HSA level was increased in
subjects who were overweight and/or with NAFLD (Supple-
mentary Figure S2). However, the oxidized HSA level was
not markedly different among the DsbA-L rs1917760 geno-
types (Figure 4); as such, the DsbA-L T/T genotype might
Figure 5 The structural equation modeling diagram of nonalcoholic fatty liver disease (NAFLD) and the disulfide bond-forming oxidore-
ductase A-like protein (DsbA-L) genotype. Lines with numbers indicate significant paths with standardized partial regression (b) coeffi-
cients (P<0.05). The e1, e2, e3, e4, and e5 indicate latent factors. Arrows represent an association between two factors. The b
values ranged from 21 to 1, with a positive value representing a positive correlation and negative value representing a negative corre-
lation. HDL-C, high-density lipoprotein cholesterol.




be associated with being overweight due to the decreased
adiponectin multimerization rather than the increased oxida-
tive stress, although further studies are needed to verify the
relationship of the DsbA-L genotype with oxidative stress
using other more sensitive oxidative stress-related markers.
Several limitations associated with the present study war-
rant mention. The subjects’ alcohol consumption and smok-
ing status were evaluated through face-to-face interviews,
which might have lacked reliability. The diagnosis of FLD
was performed by hepatic ultrasonography scanning and
was not confirmed by a liver biopsy. Another limitation of
the present study was the study design. The present study
was retrospective in nature and investigated a relatively
small number of subjects, especially of the subjects strati-
fied by the DsbA-L genotypes. Furthermore, some of the
subjects did not attend the health screening program annu-
ally throughout the observation period; thus, the number of
study subjects varied at some points of the observation
period. Notably, the decrease in the number of subjects
with the T/T genotype (20%) was less than that in the
patients with the G/G or G/T genotypes (>30%) during the
observation period (Figure 1). In the present study, we
modeled the BMI and the risk of NAFLD using a NONMEM
procedure, which enabled the quantification of several lev-
els of variability and allowed us to address unstable data
(e.g., a limited number of samples per individual at different
time points). Thus, the variation in the number of study sub-
jects during the observation period may not have had a sig-
nificant impact on the results of this study. Nevertheless, a
further large longitudinal investigation is required to verify
the present findings.
In conclusion, our population prediction model of BMI
indicated that the DsbA-L T/T genotype was significantly
associated with a high BMI. The BMI-based NAFLD predic-
tion model showed that the DsbA-L T/T genotype did not
have any direct impact on the risk of NAFLD, whereas our
structural equation model suggested that this genotype
effect might be indirectly or partially associated with the
risk of developing NAFLD through a high BMI and low adi-
ponectin multimerization. Thus, genotyping to investigate
DsbA-L polymorphism and determine the patients with the
highest risk of developing obesity may help to prevent obe-
sity, and possibly NAFLD, by facilitating targeted prevention
and treatment programs in patients with a high risk of obe-
sity; however, further larger studies are needed to verify
our findings.
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